New insider activity at Inogen ( (INGN) ) has taken place on March 5, 2025.
Senior Vice President, CFO, and Treasurer Michael J. Bourque has made a significant investment by purchasing 3,000 shares of Inogen stock, valued at $24,960. In a similar move, Director Smith Kevin Raymond Merrill acquired 11,709 shares of Inogen stock, with a total purchase price of $100,229.
Recent Updates on INGN stock
Inogen Inc’s recent earnings call revealed a mixed outlook, with notable revenue growth and strategic advancements countered by ongoing challenges. The company reported a 6.4% increase in annual revenue, driven by international and domestic business-to-business sales, and a strategic collaboration with Yuwell Medical, which is expected to enhance market presence and drive future growth. Additionally, the FDA clearance for the Simeox device expands Inogen’s product portfolio. However, the company faces a decline in direct-to-consumer and rental revenues, attributed to a downsized sales force and a shift towards private payers. Despite these challenges, Inogen achieved two consecutive quarters of adjusted EBITDA profitability and anticipates continued improvement in 2025, focusing on strategic cost management and leveraging partnerships. The forward-looking guidance suggests cautious optimism, with projected revenue growth and efforts to achieve adjusted EBITDA breakeven.
More about Inogen
YTD Price Performance: -9.36%
Average Trading Volume: 262,209
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $198.4M